Johnson & Johnson Stock Falls 5% After Q3 Profit Plunges
Johnson & Johnson (JNJ) shares fell 5.12% to $250.24 after Q3 earnings dropped 96% to $210M due to a one-time charge. Sales rose 5.9% to $25.4B. The company raised its 2026 adjusted EPS and sales guidance. Trading volume was 2.3M shares.
How this was made
The 30-second read
Why it matters
Despite a sharp GAAP net earnings decline, management raised fiscal 2026 adjusted EPS and sales guidance, which can partially offset concerns but may not fully neutralize the market’s focus on litigation-related charges.
Market read
Same-day move is explained by the Q3 earnings plunge and the market’s interpretation of litigation-charge implications, with guidance increases providing a counterweight.
What to watch
Traders may overreact to GAAP net earnings; the article highlights adjusted earnings and guidance, which could reduce the durability of the selloff if investors re-anchor to adjusted metrics.
Background
The article frames JNJ’s Q3 weakness as primarily driven by a one-time special charge tied to the proposed talc litigation resolution.
Ticker impact
Johnson & Johnson shares fell about 5% after Q3 results showed net earnings plunging 96% to $210 million, driven by a special talc litigation charge.
Likely downside bias as the market digests the sharp reported earnings drop, even with higher fiscal 2026 adjusted EPS and sales guidance.
The article ties the same-day stock decline directly to the Q3 earnings plunge and specifies the driver as a special charge, while also noting guidance was raised, creating a mixed but net-negative read-through for reported earnings quality.
Market effects
Large-cap healthcare earnings volatility may keep pressure on defensive peers if investors treat litigation charges as recurring earnings risk.
US large-cap healthcare sentiment likely softens for the day following the earnings-driven selloff.
Limited direct global spillover beyond healthcare investor sentiment around litigation-related charges.
Counterpoint
The company raised fiscal 2026 adjusted EPS and sales guidance, suggesting the core operating trajectory may be improving and the reported net earnings collapse may be largely non-recurring.
Key entities
- companyJohnson & Johnson
Healthcare company reporting Q3 results with a large GAAP net earnings decline and raised fiscal 2026 adjusted guidance.
